Wall Street brokerages forecast that Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will announce $0.29 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $0.25 to $0.35. Collegium Pharmaceutical posted earnings of $0.01 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 2,800%. The firm is scheduled to announce its next earnings report on Thursday, May 6th.
On average, analysts expect that Collegium Pharmaceutical will report full year earnings of $1.64 per share for the current financial year, with EPS estimates ranging from $1.54 to $1.72. For the next financial year, analysts expect that the business will report earnings of $2.47 per share, with EPS estimates ranging from $2.31 to $2.79. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 25th. The specialty pharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.09). Collegium Pharmaceutical had a return on equity of 12.64% and a net margin of 5.71%.
In related news, EVP Shirley R. Kuhlmann sold 6,081 shares of the company’s stock in a transaction dated Wednesday, January 20th. The stock was sold at an average price of $24.45, for a total transaction of $148,680.45. Following the sale, the executive vice president now owns 102,891 shares in the company, valued at approximately $2,515,684.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael Thomas Heffernan sold 50,075 shares of the company’s stock in a transaction dated Monday, March 15th. The shares were sold at an average price of $25.30, for a total value of $1,266,897.50. Following the sale, the director now owns 7,078 shares in the company, valued at approximately $179,073.40. The disclosure for this sale can be found here. Insiders sold a total of 139,081 shares of company stock worth $3,288,498 in the last quarter. Corporate insiders own 8.08% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in shares of Collegium Pharmaceutical by 0.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 604,534 shares of the specialty pharmaceutical company’s stock valued at $12,109,000 after purchasing an additional 4,266 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Collegium Pharmaceutical by 10.2% during the 4th quarter. UBS Asset Management Americas Inc. now owns 30,434 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 2,822 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $7,498,000. JPMorgan Chase & Co. boosted its position in shares of Collegium Pharmaceutical by 6.1% during the 4th quarter. JPMorgan Chase & Co. now owns 28,769 shares of the specialty pharmaceutical company’s stock valued at $576,000 after purchasing an additional 1,648 shares in the last quarter. Finally, Diametric Capital LP bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $448,000.
Shares of COLL opened at $23.29 on Monday. Collegium Pharmaceutical has a 12-month low of $15.66 and a 12-month high of $26.91. The business has a 50-day simple moving average of $24.15 and a two-hundred day simple moving average of $21.50. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 1.27. The stock has a market cap of $809.47 million, a PE ratio of 47.53, a PEG ratio of 0.73 and a beta of 1.27.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting.
Recommended Story: What is a SEC Filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.